Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...
HealthDay on MSN11d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid CancerGlucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback